As a potent inhibitor of the RTK KIT, an oncogenic driver in about 80% of metastatic GIST, imatinib’s authorization also initiated a new era for the development of targeted therapies against cancers with molecularly defined driver alterations. This evidence concerns the gene KIT and gastrointestinal stromal tumor.